Introduction {#S1}
============

C-C chemokine receptors 5 (CCR5) is a kind of cytokine belonging to the β chemokine receptor family of integral membrane proteins ([@B102]). CCR5 is well known (or notorious) mainly because it collaborates with human immunodeficiency virus-1 (HIV-1) when the virus enters target immunological cells ([@B90]; [@B37]). Intriguingly, most current anti-HIV drugs target CCR5. At the end of the 2018, the announcement of Chinese gene edited infants whose CCR5 genes were deleted by CRISPR-Cas9 again brought the debate about CCR5 to the forefront.

Alzheimer's disease (AD), characterized by typical pathological changes such as senile plaques and neurofibrillary tangles, is the most prevalent neurodegenerative disorder. With the aging of the population, the battle with AD will become more difficult. Although the causes and pathogenetic mechanisms remain uncertain, there is growing evidence linking neuroinflammation with AD ([@B70]; [@B50]). Numerous cytokines, e.g., tumor necrosis factor (TNF) ([@B60]), interleukin-1 (IL-1) ([@B60]), interleukin-6 (IL-6) ([@B47]), and colony-stimulating factor (CSF) ([@B136]), have been suggested to be connected with the course of AD. Additionally, many variants in immune genes such as TREM2, CD33 and CR1 were recognized by genome-wide association studies (GWAS) as genetic risk factors for AD ([@B61]; [@B81]; [@B55]; [@B45]; [@B53]).

Our receptor of interest, the chemokine receptor, is involved in substantial inflammatory diseases of the central nervous system (CNS) and functions in the recruitment and immigration of immune cells. These receptors are mainly distributed in microglia and recruited peripheral blood monocytes in the CNS ([@B29]), while they are rarely expressed on neuronal cell membranes under normal physiological conditions ([@B57]). Increased expression of CCR5 in the CNS is an inflammatory response to many neuropathological diseases, e.g., stroke ([@B65]), Parkinson's disease ([@B57]), multiple sclerosis ([@B124]; [@B130]), and Rasmussen encephalitis ([@B9]; [@B132]). At the beginning of this year, an article published in Cell ([@B65]) further attracted everyone's attention to the association between CCR5 and neuronal plasticity that is potentially relevant to neuroinflammation and AD. In this review, we will elucidate the intricate association between AD, inflammation, and CCR5.

AD and Neuroinflammation {#S2}
========================

Pathogenesis of AD {#S2.SS1}
------------------

As the most common cause of dementia, AD is still defined by the combined presence of amyloid and tau; thus, countless studies are conducted with the aim of discerning the enigma of these two pathological factors. However, all current drug clinical trials for amyloid or tau have ended in failure. Researchers are gradually moving away from the simple estimation of linear connection as proposed in the initial amyloid hypothesis ([@B120]). Several lines of evidence confirmed that vascular damage increased the risk of later cognitive impairment and finally dementia ([@B32]; [@B42]; [@B71]; [@B104]). Additionally, there are considerable disease and lifestyle determinants that could result in increased susceptibility to developing AD, e.g., traumatic brain injury, hypertension, diabetes, obesity, education, exercise, and psychological factors, except for the proverbial aging and risk genetic allele ([@B93]). Notably, most of these factors are relevant to inflammation and immunity. Consequently, a variety of hypotheses and theories of AD have been proposed, among which the inflammation hypothesis is receiving growing support ([@B91]; [@B96]; [@B115]; [@B122]). Although the reviews of neuroinflammation and AD are abundant and comprehensive (for more detail, we recommend Ref; [@B64]; [@B52]; [@B103]; [@B23]), we will focus on the relationship between microglia and neuroinflammation because microglia harbor the majority of CCR5 in the CNS.

Microglia as a Double-Edged Sword {#S2.SS2}
---------------------------------

Notwithstanding existing evidence indicating that peripheral immune cells can infiltrate brain tissue through the damaged blood-brain barrier (BBB) under pathological conditions and cause inflammation ([@B135]), native microglia and activated astrocytes, which widely reside everywhere throughout the brain, are the main contributors to neuroinflammation. Unlike neurons, astrocytes, and oligodendrocytes, microglia are considered resident immune cells from the mesoderm and function in some housekeeping work, including neurogenesis, the trimming and stimulation of synapses, the modulation of cognitive processes, and immunological surveillance. Gradual deterioration of the immune system increases vulnerability to infections and diseases as individuals age. Some altered expression of microglia-related genes that could accelerate the progression of AD has been identified in AD patients ([@B22]). Microglia isolated from postmortem aging brains also showed significant transcriptome characteristics compared with those obtained from younger brains; genes associated with cell-adhesion axon-guided cell surface receptor expression and actin assembly were specifically affected ([@B34]). Moreover, microglial cells from the aged cortex show many morphological abnormalities, including the formation of nodal processes and division processes of acellular globules ([@B125]).

The proteins that microglia produce exhibit dramatic changes during aging, neurodegeneration, and neuroinflammation. For example, secreted cytokines, displayed membrane proteins, and energy and metabolism protein needs differ drastically ([@B108]; [@B87]). However, the complex relationship between microglia, tau, and amyloid beta protein (Aβ) remains controversial. On the one hand, many studies have indicated that microglia are capable of congregating around Aβ and phagocytosing it to attenuate the pathological load. On the other hand, activated microglia could damage neurons and vascular epithelial cells, which lead to additional impairment of cognitive function ([@B43]; [@B116]; [@B24]; [@B97]; [@B123]). The distinct subtypes of microglia contribute to the AD course in a diverse manner, and the heterogeneity of pro- and anti-inflammatory timing of microglia is a formidable obstacle ([@B79]; [@B51]; [@B82]; [@B14]; [@B78]; [@B33]). Reactive microglia can accelerate the propagation of tau pathology, thereby causing a deterioration in inflammation ([@B141]; [@B114]). Deposition of Aβ worsens neurodegeneration and triggers pro-inflammatory responses. Moreover, Aβ binds to inflammatory receptors ([@B139]; [@B27]; [@B117]) and promotes immune-related transcriptional signals ([@B11]; [@B109]) ([Figure 1](#F1){ref-type="fig"}). When microglia and astrocytes clear Aβ through phagocytosis and intracellular degradation, many transmembrane receptors (e.g., LRP-1 and ATP-binding cassette transporter family) bind to Aβ, and most of these receptors are essential in immune and inflammatory responses ([@B4]; [@B18]).

![Alzheimer's disease, neuroinflammation and CCR5. **(Upper left)** The schematic graph of an AD patient's brain. The brain shows varying degrees of shrinkage and vascular inflammation. The gray patches represent neuroinflammation in different regions of AD brain insults. **(Lower left)** Brain slice of a severe AD patient from the location of shaded plane in the **(Upper left)** graph. Apparent shrinkage and numerous Aβ depositions are presented. The black dots represent Aβ deposits. **(Right)** The magnified version of the box in the lower left graph. The Aβ deposits are surrounded by activated astrocytes (agate green) and microglia (purple). The neurons (yellow) are inevitably affected by these neighbors, which leads to disorders of electrical and chemical signal conduction. The blue triangles represent the expression of CCR5. Activated astrocytes and microglia produce abundant CCR5, while neurons express few of them. The radial orange circles are Aβ deposits.](fnagi-11-00209-g001){#F1}

Molecular Receptor Spectrum of Neuroinflammation {#S2.SS3}
------------------------------------------------

The theoretical framework regarding how inflammation interacts with the development of AD has been widened and explored on an unprecedented scale. Internationally renowned pharmaceutical companies have already started multiple clinical drug trials on the anti-inflammatory treatment of AD ([@B23]). Despite cellular components (e.g., microglia, astrocytes, and endothelial cells), an increasing number of receptors, membrane proteins and metabolic enzymes have become candidates for further research and clinical trials. For example, positive modulation of a7 nicotinic acetylcholine receptors (a7nAChRs) had therapeutic potential for its anti-inflammatory effects ([@B28]). The lower dose of colony-stimulating factor 1 receptor (CSF1R) inhibitors led to increased hippocampal-dependent spatial memory ([@B121]). Angiotensin II receptor blockers (ARBs) were considered a neuroprotective candidate against early damage factors to neurons, astrocytes, microglia, cerebrovascular endothelial, and BBB; consequently, ARBs prevent cognitive loss and dementia ([@B112]). Mimetics of glucagon-like peptide 1 (GLP-1) receptor agonists, first designed to treat diabetes, were capable of reducing inflammation, oxidative stress, and apoptotic signaling and protecting memory formation ([@B56]). In addition to membrane receptors, a substantial number of studies revealed that nuclear receptors could be potential interventional targets to suspend dementia progression in AD ([@B86]). Notably, numerous studies have focused on various inflammatory receptors and diverse signaling pathways. Among these components, chemokine receptors, which are mainly studied in immunology, deserve further attention. The birth of Chinese gene edited infants has greatly enriched scientific theories because some studies showed that CCR5 deficiency could improve both prognosis and neuronal plasticity after stroke and traumatic injury, which encouraged an unprecedented CCR5 research boom ([@B65]).

CCR5 {#S3}
====

CCR5: Structure, Distribution, and Function {#S3.SS1}
-------------------------------------------

CCR5 belongs to the seven transmembrane G-protein coupled receptors (GPCRs) that transmit signals via heterotrimeric G proteins ([@B101]). CCR5 consists of 7 hydrophobic transmembrane domains with an extracellular N-terminus and cytoplasmic C-terminus, ranging in length from 340 to 370 amino acids ([@B99]). CCR5 is the receptor for nearly 10 chemotactic proteins of the β chemokine family, which are also named CC chemokines ([@B44]). In humans, the gene encoding the CCR5 protein is situated in the short (p) arm at position 21 on chromosome 3.

In the immune system, CCR5 widely resides on the surface of antigen-presenting cells (e.g., macrophages, dendritic cells), effector lymphocytes and regulatory T cells ([@B44]). The corresponding ligands are presented on effector T cells and natural killer cells ([@B92]; [@B76]; [@B54]). CCR5 regulates chemotaxis and cell activation through interactions with MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), MCP-2 (CCL8), CCL11 (eotaxin), HCC-1 (CCL14a), and HCC-4 (CCL16) ([@B2]).

CCR5 is widely known because it provides access for HIV-1 to invade host immune cells. The gp120 envelope protein is a chemokine mimic; thus, it can bind to CCR5 during HIV infection ([@B90]). Additionally, CCR5 can accelerate the transmission of the R5-strain of the HIV-1 virus ([@B74]). CCRΔ32 is a 32-base-pair deletion that inserts a premature stop codon into the CCR5 receptor locus, leading to receptor dysfunction. Homozygous carriers of this mutation cannot be infected with M-tropics strains of HIV-1 ([@B26]; [@B36]; [@B107]; [@B67]).

Several lines of cancer cells (e.g., breast and prostate cancer cells), instead of normal epithelial cells, express a high level of CCR5, which help the cancer transformation process ([@B133]; [@B25]). Furthermore, the chemotherapy resistance of cancer stem cells could be partly accredited to the expression of CCR5 ([@B63]).

In the CNS, these receptors are produced by microglia, astrocytes, and endothelial cells (normally undetectable on neurons) ([@B118]; [@B84]; [@B127]). All existing evidence suggests that CCR5 participates in neuroinflammation and neuroimmunology, including microglial activation ([@B21]; [@B10]), microglial chemotaxis ([@B6]; [@B72]), monocyte/macrophage chemotaxis ([@B40]), lymphocyte chemotaxis ([@B30]; [@B40]), brain development and cell differentiation ([@B7]; [@B68]; [@B84]; [@B72]), neuronal transmission ([@B1]; [@B15]; [@B134]) and anti-microorganism functions ([@B85]; [@B48]; [@B12]). Under the same conditions, neuronal death was more notable in the brains of CCR5−/− mice than in those of CCR5+/+ mice ([@B49]). Knockout of the CCR5 gene was associated with the inadequate development and maturation of dopaminergic neurons ([@B16]).

CCR5: Signal Pathway {#S3.SS2}
--------------------

CCR5 activates the cellular signaling pathway through G proteins, pertussis-sensitive heterotrimeric G proteins and G protein-independent pathways ([@B99]). The binding of a chemokine ligand to CCR5 results in conformational changes in G proteins, which will enable various signaling cascades, including those of the phosphoinositide-3 kinase (PI3K), protein kinase C (PKC), and mitogen-activated protein kinases (MAPK), as well as calcium influx ([@B99]; [@B128]). At present, G-protein-independent signaling pathways involving the Janus kinases (JAK), pyk2 kinase, and arrestin pathways have been identified ([@B20]; [@B89]). These cascades activate various cellular functions, cytoskeleton recombination, and chemotaxis. Calcium flux is an essential procedure for sequent signal activation in the CNS. Given that various types of cells express CCR5, it is not impossible that its diverse biological effects require more than G-protein-initiated pathways. The different chemokine ligands that CCR5 binds to determine distinct signaling pathways accounting for the pleiotropic effects of chemokine signaling ([@B88]; [@B62]).

Additionally, blockage of CCR5 signaling could not only lead to rejection of HIV but also elicit neuroprotective mechanisms and promote neuron survival, which will alleviate HIV-associated dementia ([@B66]; [@B17]; [@B80]).

The Efficacy of CCR5 Antagonists {#S3.SS3}
--------------------------------

The promising development of CCR5 receptor inhibitors is largely based on CCR5's identity as a necessary pathway for AIDS infection. The only first-generation CCR5 antagonist that the Food and Drug Administration (FDA) approved, Maraviroc, was well tolerated and showed excellent repression of viral load in patients whose highly active antiretroviral therapy (HAART) failed but not in treatment-naïve patients([@B74]; [@B119]; [@B131]). The high efficacy of maraviroc has set the tone for second-generation CCR5 antagonists, which account for the failures of aplaviroc and vicriviroc in clinical trials ([@B46]; [@B73]; [@B126]). Various modified and innovative second-generation CCR5 antagonists \[e.g., piperidine amide compounds ([@B59]; [@B31]; [@B126]), piperazines and diketopiperazines ([@B75])\] demonstrated guaranteed efficacy in I/II clinical trials, especially the dual CCR5/CCR2 antagonists ([@B83]).

However, more data have revealed that CCR5 antagonists function in other disease courses. Dual CCR5/CCR2 antagonists and cenicriviroc could inhibit the progression of non-alcoholic fatty liver disease ([@B129]; [@B95]). In addition, cenicriviroc could reduce liver injury in cholestatic rodents ([@B142]). Moreover, the inhibition of lymphocyte migration caused by CCR5 blockade could alleviate graft-versus-host disease ([@B106]). Could the CCR5 blockade provide relief from AD?

Ad and CCR5 {#S4}
===========

The definite relationship between AD and CCR5 remains an open debate. Disputable results from basic experimental studies have diverged into two opposed groups. Most of studies demonstrated that the expression of CCR5 contributes to the development of AD ([Table 1](#T1){ref-type="table"}), while the minority demonstrated that CCR5 could improve memory function in AD ([Table 2](#T2){ref-type="table"}). However, all existing epidemiologic studies confirmed that there was no association between the CCR5Δ32 allele and AD risk. Therefore, the entanglement of AD and CCR5 urgently needs to be addressed ([Table 3](#T3){ref-type="table"}).

###### 

Studies that CCR5 expression exacerbated AD.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          **Discovery**                                                                                                                                                             **Title**                                                                                                                                                                                                                                            **Author**   **Model**        **Methods**
  ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ---------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Direct evidence**     Microglia with CCR5 expression are associated with deposition of Aβ.                                                                                                      Immunohistochemical study of the β-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains.                                                                                                                     [@B138]      Human            Immunohistochemistry of brain tissue of post mortem human being.

                          CCR5−/− mice had less activation of microglia and astrocytes after injection of Aβ into lateral ventricle.                                                                Role of the macrophage inflammatory protein- 1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid\                                                                      [@B100]      Mice             Knockout of mice CCR5 gene.
                                                                                                                                                                                                    peptide.                                                                                                                                                                                                                                                                           

                          CCR5 antagonists attenuated the neuroinflammation of sub cutaneous administration of lipopolysaccharide by decreasing the number of activated microglia and astrocytes.   Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120.                                                                                                                             [@B5]        Rats             Administration of CCR5 antagonist to rats preinjected with lipopolysaccharide.

                          CCR5 participated in the impairment of learning and memory in AD by activating microglia and promoting T cells transendothelial migration.                                Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's\                                                                                                                                                      [@B77]       Human and rats   CCR5 detection of peripheral blood mononuclear cells from AD patients and healthy controls; Peripheral intravenous injection of Aβ in rats, followed by administration of CCR5 CCR5 antagonist (2D7 mAb).
                                                                                                                                                                                                    disease.                                                                                                                                                                                                                                                                           

                          The ligands of CCR5, CCL3 and CCL4, were upregulated in microglia isolated from AD patients' brain and stimulated with Aβ.                                                Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia.                                                                                                                                                      [@B137]      Human            Gene array technology.

                          The CCR5 expression of PBMC from AD patients was significantly higher and *in vitro* PBMC culture with Aβ increased the CCR5 expression.                                  Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease.                                                                                                                                                                    [@B105]      Human            CCR5 detection of PBMC from AD patients and healthy controls.

                          The proportion of cells expressing CCR5 (Th1 cells and dendritic cells) was greater in AD patients.                                                                       Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease.                                                                                                                                                           [@B41]       Human            CCR5 detection of PBMC from AD patients and healthy controls.

                          Aβ could increase CCR5 expression through cellular signaling of c-Raf, ERK-1/ERK-2, and c-Jun NH2-terminal kinase in PBMC.                                                Mechanism of amyloid peptide induced CCR5 expression in monocytes and its inhibition\                                                                                                                                                                [@B39]       Human            CCR5 detection of PBMC from AD patients and healthy controls and *in vitro* administration of siRNA for inhibiting CCR5 relevant signal pathways.
                                                                                                                                                                                                    by siRNA for Egr-1.                                                                                                                                                                                                                                                                

                          The curcumin inhibited Aβ associated expression of CCR5 by preventing Egr-1 DNA binding to the promoter of CCR5.                                                          Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response1 transcription factor.                              [@B39]       Human            Administration of curcumin into PBMC culture *in vitro*.

                          The CCR5 antagonist (DAPTA) of monocyte chemotaxis, was proved to reduce chronic neuroinflammation of AD.                                                                 Update on [D]{.smallcaps}-Ala-Peptide T-Amide (DAPTA): A\                                                                                                                                                                                            [@B110]      Rats             Administration of DAPTA to AD rats.
                                                                                                                                                                                                    Viral Entry Inhibitor that Blocks CCR5 Chemokine Receptors; Chemokine receptor 5 antagonist [D]{.smallcaps}-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's\                                 
                                                                                                                                                                                                    disease.                                                                                                                                                                                                                                                                           

  **Indirect evidence**   Both knockout of CCR5 gene and administration of maraviroc helped new formation of neuronal connections.                                                                  CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.                                                                                                                                                                   [@B65]       Mice             Knockout of CCR5 gene and administration of maraviroc.

                          Weakening the function of CCR5 in mouse led to enhanced LTP and hippocampus-dependent\                                                                                    CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory.                                                                                                                                                                    [@B13]       Mice             Knockout of CCR5 gene.
                          memory.                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Studies that CCR5 expression improved AD.

  **Discovery**                                                                            **Title**                                                                                                                 **Author**   **Model**   **Methods**
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------ ----------- ---------------------------------------------------------------------------------------
  CCR5−/− mice showed higher Aβ deposit and impaired long-term and spatial memory.         CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function.                                 [@B140]      Mice        Knockout of mice CCR5 gene.
  CCR5 expression reduced in amyloid precursor protein plus presenilin-1 (APP/PS1) mice.   Changes in Chemokines and Chemokine Receptors Expression in a Mouse Model of Alzheimer's Disease.                         [@B94]       Mice        Detection of CCR5 in APP/PS1 mice by quantitative RT-PCR and Western-blot techniques.
  CCR5 reduction resulted in an increase of Aβ deposits and impairment of memory.          CCR5 deficiency accelerates lipopolysaccharide-induced astrogliosis, amyloid-beta deposit and impaired memory function.   [@B58]       Mice        Knockout of CCR5 gene in mice.
  CCR5 gene expression was significantly reduced over time in Tau-P201L mice.              CXCR4 involvement in neurodegenerative diseases.                                                                          [@B3]        Mice        Tau transgenic mouse models.
  CCR5−/− mice showed higher Aβdeposition.                                                 CCR5 deficiency induces astrocyte activation, Aβ deposit and impaired memory function.                                    [@B140]      Mice        Knockout of CCR5 gene in mice.

###### 

Studies that show no association between CCR5 expression and AD development.

  **Discovery**                                                                                                                           **Title**                                                                                                                                                              **Author**   **Model**   **Methods**
  --------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------- ----------------------
  The CCR5Δ32 gene mutation in Spanish is not associated with the AD risk.                                                                The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease.                                                                       [@B98]       Human       Epidemiologic study.
  The CCR5Δ32 allele did not did not contribute to the risk of AD.                                                                        Chemokines (RANTES and MCP-1) and chemokine- receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease.                                      [@B57]       Human       Epidemiologic study.
  No significant difference was shown in the distribution of CCR5 between AD patients and healthy controls in Iran.                       Ccr2-64i and Ccr5 Δ32 Polymorphisms in Patients with Late-Onset Alzheimer's disease; A Study from Iran (Ccr2-64i And Ccr5 Δ32 Polymorphisms in Alzheimer's disease).   [@B69]       Human       Epidemiologic study.
  No significant differences was demonstrated in genotype distribution and CCR5Δ32 allelic frequency both in women and in men in Italy.   Association between the Polymorphism of CCR5 and Alzheimer's Disease: Results of a Study Performed on Male and Female Patients from Northern Italy.                    [@B8]        Human       Epidemiologic study.

The Major Group: CCR5 Exacerbates AD ([Table 1](#T1){ref-type="table"}) {#S4.SS1}
-----------------------------------------------------------------------

Memory, learning and plasticity processes in hippocampal and cortical circuits involve electrochemical activity of neurons, including long-term potentiation (LTP), release of glutamate, activation of *N*-Methyl-[D]{.smallcaps}-aspartic acid (NMDA) receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, and the generation of new dendritic spines and axons. [@B13] reported that weakening the function of CCR5 in the mouse barrel cortex improved MAPK/CREB signaling, which resulted in enhanced spike-timing-dependent plasticity and experience-dependent plasticity ([Figure 2](#F2){ref-type="fig"}). Consequently, LTP and hippocampus-dependent memory significantly improved, while neuronal CCR5 overaction led to memory deficits ([@B13]). This cornerstone study underlies the foundation of the relationship between memory and CCR5, which also implies a potential discoverable link between CCR5 and AD. The increase in both CCR5 and CCR3 on some reactive microglia was found in AD patients and associated with amyloid deposition ([@B138]). After the administration of Aβ into the lateral ventricle of CCR5−/− mice, the activation of microglia and astrocytes was decreased compared with that in CCR5 wild-type mice ([@B100]). CCR5−/− mice showed decreased astrocytosis and microgliosis in the hippocampus after Aβ injection, which resulted from decreased expression of cyclooxygenase-2 and inducible nitric oxide (NO) synthase, as well as reduced activation of nuclear factor-κB (NF-κB), activator protein-1 and cyclic AMP response element-binding protein ([@B100]). In humans, there were more widespread reactive astrocytes with CCR5 expression in AD than in healthy ([@B138]) controls. In addition, the impairment of memory and synaptic dysfunction caused by Aβ were alleviated in CCR5−/− mice ([@B100]). Similarly, both knockout of the CCR5 gene and administration of maraviroc (FDA-approved anti-HIV drug) could heighten plasticity in the premotor cortex proximal to the stroke site and upregulate CREB and DLK signaling in neurons, which finally aided in the formation of new connections in the contralateral premotor cortex ([@B65]). Although this conspicuous study did not connect CCR5 with AD, it suggested that CCR5 and its signaling pathways had a pivotal impact on the generation and regeneration of dendritic spines and synapses. Peripheral blood immune cells can filter into the CNS with the help of CCR5 ([@B77]). [@B77] suggested that CCR5 participated in the impairment of learning and memory in AD by activating microglia and promoting T cell transendothelial migration through the Rho/ROCH pathway. CCL3 and CCL4, as ligands for CCR5, were upregulated in microglia isolated from AD patient brains and stimulated with Aβ ([@B137]). In addition, peripheral blood mononuclear cell (PBMC) analysis suggested that the expression of both CCR5 and CCR2 were augmented in AD patients compared with those in control subjects ([@B105]). Further experiments suggested that acetylcholinesterase inhibitor (ACEI) was capable of decreasing the expression of CCR5 and CCR2 in the PBMCs of AD patients, while *in vitro* administration of Aβ increased their expression in PBMCs ([@B105]). Similar results were also obtained by [@B41], who found that the distribution of cells expressing CCR4 (expressed on Th2 cells) and CCR5 (Th1 cells and dendritic cells) was also greater in patients and was more distinguished on CD4+ than CD8+ T cells. A CCR5 antagonist could reduce the number of active astrocytes and microglia after lipopolysaccharide injection, which implied that CCR5 was involved in neuroinflammation related to AD ([@B19]). [@B39] indicated that Aβ could increase CCR5 expression through cellular signaling of c-Raf, ERK-1/ERK-2, and c-Jun NH2-terminal kinase in PBMCs. As mentioned above, CCR5 is involved in neuroinflammation, wherein various CCR5 antagonists can attenuate the neuroinflammation associated with AD. D-Ala-peptide T-amide (DAPTA), a kind of CCR5 antagonist of monocyte chemotaxis, was shown to reduce chronic neuroinflammation by blocking the release of the proinflammatory cytokines TNF-α and IL-1 ([@B111]; [@B110]). After the administration of Egr-1 siRNA, Aβ-associated CCR5 expression and its concomitant ligands decreased significantly ([@B39]). Curcumin also inhibited the Aβ-associated expression of CCR5 by preventing Egr-1 DNA binding to the promoter of CCR5 ([@B38]).

![The signaling pathway of CCR5 and neuronal plasticity. The arrow represents promotion, while the ⊥ represents inhibition. The thickness of the arrow and ⊥ indicates the intensity of promotion or inhibition.](fnagi-11-00209-g002){#F2}

The Minor Group: CCR5 Improves AD ([Table 2](#T2){ref-type="table"}) {#S4.SS2}
--------------------------------------------------------------------

However, CCR5 expression was reduced, and both chemokine CCL3 and CCL4 chemokine expression levels were augmented in amyloid precursor protein plus presenilin-1 (APP/PS1) mice, which are a common model for AD studies ([@B94]). Additionally, [@B58] showed that CCR5 reduction led to higher Aβ deposition and impairment of memory. Lipopolysaccharide injection of CCR5 knockout mice significantly increased astrogliosis and Aβ deposition compared with those in CCR5 wild-type mice ([@B58]). Within the hippocampus and cerebral cortex of Tau-P201L mice, which is another frequently used model for AD, CCR5 gene expression was significantly reduced over time compared with that in wild-type mice, while no distinction was found between other brain regions([@B3]). CCR5−/− mice showed a higher level of Aβ, which was related to astrocyte activation and CCR2 overexpression. These changes finally caused memory impairments ([@B140]).

No Epidemiological Link Between AD and CCR5 ([Table 3](#T3){ref-type="table"}) {#S4.SS3}
------------------------------------------------------------------------------

Despite the fact that experimental studies were full of controversies and the conclusive relationship between AD and CCR5 remained unknown, the epidemiological evidence was certain and negative. Several epidemiological studies confirmed that there was no differential distribution of the CCRΔ32 deletion in AD patients and controls in Italy ([@B8]). Moreover, no differences were observed by gender stratification, by the presence of the ApoE q4 allele, or by the age at onset in genotype distribution and allelic frequency ([@B8]). Identical results were found in Spanish and Iran: the CCR5Δ32 allele was not a correlative factor for AD ([@B35]; [@B98]; [@B113]).

Conclusion and Outlook {#S5}
======================

The definite mechanism of AD remains unclear, but our understanding of AD has far exceeded the two typical pathological manifestations---Aβ and tau. The neuroinflammation theory of AD is fascinating an increasing number of researchers. Currently, more than 5000 studies about AD and neuroinflammation are available on PubMed, and the number is expanding. CCR5 expression was strongly related to microglia and inflammation, which validated an inseparable relationship between inflammation, Alzheimer's disease, and CCR5 ([@B3]). As the most notable receptor among the chemokine receptor family, the accurate function and subsequent signaling pathways of CCR5 have been well studied. Available epidemiological evidence could provide no connection between the CCR5Δ32 gene and AD ([@B98]; [@B113]; [@B8]). However, given that all of the epidemiological evidence was based on genotype and performed more than a decade ago, potential links may lie deeper than the superficial genotype, such as translational modulation, proteomics, and epigenetics. Despite the controversy, it cannot be denied that CCR5 plays an important role in the process of LTP, cortical plasticity, learning and memory ([@B13]). We posited that the reason for experimental conflicts between CCR5 and AD are as follows: the animal models and the methods the authors used for acquiring AD models were varied. Furthermore, compared with administration of small interfering RNA (siRNA), maraviroc and other antagonists, the effect of total knockout of the CCR5 gene could lead to an enormous impact on cellular signal pathways inside the membrane. Further investigation should take these factors into account. Future studies of molecular mechanisms of subsequent intracellular signal pathways caused by CCR5 activation would shed new light on this entanglement between AD and CCR5.
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